Which is better, DHR or GMAB?

On the Buffett-Fit framework, Genmab A/S (GMAB) currently grades higher than DHR — 65/100 (C grade) vs 63/100 (D). That said, "better" depends on which framework you trust — DHR wins on Benjamin Graham; GMAB wins on Warren Buffett, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy DHR or GMAB?

This page is an educational comparison, not investment advice. Both DHR and GMAB are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is DHR better than GMAB for value investing?

The two are close on the headline Buffett-Fit score (63/100 vs 65/100), so "better for value investing" depends on which pillar you weight most. The five Buffett pillars + six other frameworks are broken down side-by-side on this page so you can pick the one that fits your style.

What's the difference between DHR and GMAB on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). DHR currently scores 63/100 (D grade); GMAB scores 65/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, DHR or GMAB?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. DHR and GMAB are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, DHR or GMAB?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are DHR and GMAB both Healthcare stocks?

Yes — both Danaher Corporation (DHR) and Genmab A/S (GMAB) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this DHR vs GMAB comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Danaher

Genmab A/S

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

DHR

Danaher

Market cap

$121.74B

Sector

Healthcare

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

Overall winner

Genmab A/S GMAB

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	DHR	GMAB	Winner
Warren Buffett	63D	65C	GMAB
Benjamin Graham	69B	64C	DHR
Philip Fisher	47D	48D	GMAB
Peter Lynch	22F	25F	GMAB
Joel Greenblatt	45D	76B	GMAB
Charlie Munger	54D	68C	GMAB
Terry Smith	52D	71C	GMAB

Side-by-side metrics

Metric	DHR	GMAB
Market cap	$121.74B	$16.5B
P/E (TTM)	31.1x	6.2x
EV/EBIT	24.8x	12.0x
ROIC (TTM)	5.73%	43.78%
Gross margin	60.68%	93.88%
Net margin	14.89%	18.23%
Revenue CAGR 5y	-4.43%	-18.45%
EPS CAGR 5y	-12.8%	-23.48%
Debt / Equity	0.3x	0.1x
Dividend yield	0.84%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

DHR leads on

Dividend yield0.84%vs 0.0%+100%
Market cap$121.74Bvs $16.5B+86%
Revenue CAGR 5y-4.43%vs -18.45%+76%
EPS CAGR 5y-12.8%vs -23.48%+45%

GMAB leads on

ROIC (TTM)43.78%vs 5.73%+87%
P/E (TTM)6.2xvs 31.1x+80%
Debt / Equity0.1xvs 0.3x+79%
EV/EBIT12.0xvs 24.8x+52%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Danaher

Genmab A/S

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like DHR

More like GMAB

Related on invest-like

Key terms in this analysis